Status: Recruiting
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor necrosis factor (TNF)α therapy.
Participants needed: 600
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: MoonLake Immunotherapeutics AGUpdated: Jul 13, 2026Locations: 139
Eligibility criteria
Participants must be ≥18 years of age . [+5]
Participants with a known hypersensitivity to sonelokimab or any of its excipien... [+7]